Ola Bratt1, Hans Lilja. 1. aNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK bDepartment of Clinical Sciences cDepartment of Laboratory Medicine, Lund University, Lund, Sweden dDepartment of Laboratory Medicine eDepartment of Surgery (Urology) fDepartment of Medicine (GU-Oncology), Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Abstract
PURPOSE OF REVIEW: Prostate-specific antigen (PSA) testing provides significant benefits by reducing prostate cancer mortality, but also leads to important harms by detecting clinically insignificant cancers. Hence, there are urgent needs for complementary tools for middle-aged men with modest PSA elevations in blood. This review includes research on prostate cancer biomarkers in blood published from March 2013 through August 2014. RECENT FINDINGS: Research progress has been made mainly on PSA as a predictive marker and in the field of kallikrein-based tests: [-2] proPSA, the prostate health index, and a panel of four kallikrein markers. As men with PSA levels below age-median are at very low 20-year risk of metastatic prostate cancer, individualized screening intervals, based on PSA levels, may help in reducing screening costs, prostate biopsies, and detection of insignificant cancer. Statistical models based on kallikrein-markers in blood improve the specificity at modestly elevated PSA (2-10 ng/ml), eliminate unnecessary biopsies, and help selecting men at risk of significant prostate cancer for biopsy or imaging. SUMMARY: Individualized, risk-adapted PSA testing intervals and reflex-testing of kallikrein-markers for men with modestly increased PSA values may decrease the harms of screening. However, the clinical value of the proposed testing algorithms and additional tests awaits definitive confirmation in prospective trials.
PURPOSE OF REVIEW: Prostate-specific antigen (PSA) testing provides significant benefits by reducing prostate cancer mortality, but also leads to important harms by detecting clinically insignificant cancers. Hence, there are urgent needs for complementary tools for middle-aged men with modest PSA elevations in blood. This review includes research on prostate cancer biomarkers in blood published from March 2013 through August 2014. RECENT FINDINGS: Research progress has been made mainly on PSA as a predictive marker and in the field of kallikrein-based tests: [-2] proPSA, the prostate health index, and a panel of four kallikrein markers. As men with PSA levels below age-median are at very low 20-year risk of metastatic prostate cancer, individualized screening intervals, based on PSA levels, may help in reducing screening costs, prostate biopsies, and detection of insignificant cancer. Statistical models based on kallikrein-markers in blood improve the specificity at modestly elevated PSA (2-10 ng/ml), eliminate unnecessary biopsies, and help selecting men at risk of significant prostate cancer for biopsy or imaging. SUMMARY: Individualized, risk-adapted PSA testing intervals and reflex-testing of kallikrein-markers for men with modestly increased PSA values may decrease the harms of screening. However, the clinical value of the proposed testing algorithms and additional tests awaits definitive confirmation in prospective trials.
Authors: Ping Tang; Leon Sun; Matthew A Uhlman; Thomas J Polascik; Stephen J Freedland; Judd W Moul Journal: Cancer Date: 2010-10-15 Impact factor: 6.860
Authors: Brian T Helfand; Stacy Loeb; Qiaoyan Hu; Phillip R Cooper; Kimberly A Roehl; Barry B McGuire; Nikola A Baumann; William J Catalona Journal: J Urol Date: 2013-02-27 Impact factor: 7.450
Authors: Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2004 Jan-Feb Impact factor: 508.702
Authors: Massimo Lazzeri; Alexander Haese; Alexandre de la Taille; Joan Palou Redorta; Thomas McNicholas; Giovanni Lughezzani; Vincenzo Scattoni; Vittorio Bini; Massimo Freschi; Amy Sussman; Bijan Ghaleh; Philippe Le Corvoisier; Josep Alberola Bou; Salvador Esquena Fernández; Markus Graefen; Giorgio Guazzoni Journal: Eur Urol Date: 2013-01-24 Impact factor: 20.096
Authors: Eduardo García-Cruz; Albert Carrión Puig; Alejandro García-Larrosa; Andrea Sallent; Roberto Castañeda-Argáiz; Marta Piqueras; María Jose Ribal; Asier Leibar-Tamayo; Javier Romero-Otero; Antonio Alcaraz Journal: Scand J Urol Date: 2012-11-27 Impact factor: 1.612
Authors: I Heidegger; H Klocker; E Steiner; V Skradski; M Ladurner; R Pichler; G Schäfer; W Horninger; J Bektic Journal: Prostate Cancer Prostatic Dis Date: 2013-10-29 Impact factor: 5.554
Authors: Quach Truong; Irene O Justiniano; Aline L Nocon; Julie T Soon; Sandra Wissmueller; Douglas H Campbell; Bradley J Walsh Journal: J Cancer Date: 2016-05-21 Impact factor: 4.207